Navigation Links
Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting

miting cardiac effects as well as effects on the thyroid hormone axis, muscle metabolism and bone turnover. Metabasis believes that the combination of a TR beta-selective receptor agonist and liver-targeting could harness the efficacy of the approach by avoiding extra-hepatic activation of TR alpha receptors and TR beta receptors that may lead to these therapy-limiting side effects.

"MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol, serum triglycerides and liver fat," stated Dr. Mark Erion, executive vice president of research and development and chief scientific officer of Metabasis. "MB07811 combines a novel agonist selective for the beta isoform of the thyroid hormone receptor with our proprietary, liver-targeting HepDirect(R) prodrug technology. The combination of beta receptor selectivity, liver-targeting and other structural characteristics that limit extra-hepatic activity provides a product candidate that exhibits significant efficacy while avoiding side effects commonly associated with activation of thyroid hormone receptors outside the liver. If we can demonstrate these characteristics in humans, it should provide important evidence that MB07811 and this class of drugs could represent an exciting new therapeutic approach for treating hyperlipidemia."

Dr. Paul Laikind, president and chief executive officer of Metabasis, said, "The results of these studies and others supported the decision to initiate the clinical development of MB07811. The first human clinical study was successfully completed late last year and we expect to start a Phase 1b multiple dose study in healthy volunteers with moderately elevated LDL cholesterol by the end of this quarter."

About Metabasis (www.mbasis.com):

Metabasis Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs to address some of the world's most widespread an
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
2. Metabasis Therapeutics to Present Poster at American Association for Cancer Research
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... (OFT) approval condition to the announced tender offer for all of ... As a result of the waiver, the transaction is no longer ... offer on January 24, 2014 following the currently scheduled expiration time, ...
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
(Date:7/10/2014)... (PRWEB) July 10, 2014 Register to ... DataSite recently streamed the live webinar ‘Capitalizing on the ... from a group of several M&A experts in the ... the broader energy transaction marketplace. These experts shared their ... the deal market in this sector has been revitalized. ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 ... and believes that having family close by during ... difference in whether or not the process is ... of its website at http://www.bestdrugrehabilitation.com/success-stories/ . , ... and video testimonials from several Best Drug Rehabilitation ...
(Date:7/10/2014)... AURORA, Colo. (July 8, 2014) A new study ... some modest improvements, poor oral health remains a major ... overall. , "The oral health among Native Americans is ... the rest of the country," said Terrence Batliner, DDS, ... Health Research at the School of Public Health. "The ...
(Date:7/10/2014)... 10, 2014 (HealthDay News) -- Adults with dyslexia are ... as children or teenagers than people who don,t have ... Dyslexia, which affects up to 10 percent of ... that 35 percent of adults with this condition said ... 7 percent of those without dyslexia. "Even after ...
(Date:7/10/2014)... Thompson HealthDay Reporter THURSDAY, ... wars that break out regularly between outspoken celebrities or loudmouth ... own relationship, a new study suggests. High amounts of ... if the couple is in a long-term relationship, according to ... In turn, that friction can lead to cheating and breakups, ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Study finds widespread oral health problems among Navajo 2Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3
... from avian flu, bringing the total number of deaths from ... 27, a Tangerang resident, died late Friday and Jakarta resident ... two and three days of treatment in a hospital here ... flu," said an official at the Indonesian health ministry. ...
... a secret so painful that they even keep it from ... the University of Virginia, the secret exists, //and it’s big. ... high expectations for almost every area of their lives, too ... who is one of the world’s preeminent experts on women’s ...
... graduate student in the Section of Microbial Pathogenesis at ... path taken by Campylobacter// jejuni (campylobacter), as it infects ... the most common causes of diarrhea worldwide, strikes 2.4 ... few unpleasant days, but it can be life threatening ...
... prevailing trend among kids of today, who have turned ... options.// ,Researchers from university of waterloo conducted ... about eating wrong from a tender age. Parents ... which is a leading cause of increasing obesity rates, ...
... knows that a diet laden with fats and sugar, combined ... smoking is a recipe for// major problems including diabetes and ... need to realize that those same bad habits in children ... road. ,The good news: The fix is ...
... findings of a study appearing in the January 2007 issue ... discovered histamine,// the inflammatory compound released during allergic reactions that ... ,They say that histamine can be produced in large amounts ... that is the major component of pus. Pus, a fluid ...
Cached Medicine News:Health News:Women's Sex Lives Mediocre 2Health News:The Uncommon Pathway of Campylobacter Jejuni 2Health News:Cure for Most Heart Attacks Is Free, but It's Important to Start Young 2Health News:Cure for Most Heart Attacks Is Free, but It's Important to Start Young 3Health News:WBC in Lung Produces Histamine: Study 2Health News:WBC in Lung Produces Histamine: Study 3
Foldable Hydrophilic IOL with UV Absorber....
The STAAR ELASTIC LENS®, is a single piece silicone lens to be placed completely in the capsular bag....
... Engineers at Pfizer used wavefront sensing ... Optic Technology. Innovative TECNIS features a patented ... spherical aberration, which compensates for the positive ... result, TECNIS is the first and only ...
... PhacoFlexII SI30NB is foldable silicone ... it's patients. It is used ... SI30NB is indicated for primary ... of aphakia in adults (over ...
Medicine Products: